OVERVIEW
The global diagnostic companion market is projected to hit USD 7.78 billion by 2025, rising over the forecast period at a CAGR of 13.34%. The advantages of companion diagnostics, the the need for targeted treatment, the the importance of personalized medicine, the the global incidence of cancer and the ever-rising application areas of companion diagnostics drive the growth of the global companion diagnostics industry.
TABLE OF CONTENT
1 Global Companion Diagnostics Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Global Companion Diagnostics Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography
4 Global Companion Diagnostics Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis
5 Global Companion Diagnostics Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies
6 Global Companion Diagnostics Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7 Global Companion Diagnostics Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)
8 Global Companion Diagnostics Market – By Product & Service (Market Size – &
million/billion)
8.1 Assay kits & Reagents
8.2 Software & Services
9 Global Companion Diagnostics Market – By Technology
9.1 Polymerase Chain Reaction (PCR)
9.2 In Situ Hybridization (ISH)
9.3 Next-Generation Sequencing (NGS)
9.4 Immunohistochemistry (IHC)
9.5 Others
10 Global Companion Diagnostics Market – By Indication
10.1 Cardiovascular
10.2 Neurological Diseases
10.3 Cancer
10.4 Infectious Diseases
10.5 Others
11 Global Companion Diagnostics Market – By End-User
11.1 Pharmaceutical & Biopharmaceutical Companies
11.2 Reference Laboratories
11.3 CROs
11.4 Others
12 Global Companion Diagnostics Market – By Geography (Market Size – & million/billion)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 U.K
12.3.2 Germany
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Rest of APAC
12.5 Rest of the World
12.5.1 South America
12.5.2 Middle East
12.5.3 Africa
13 Global Companion Diagnostics Market – Entropy
13.1 New product launches
13.2 M&A’s, collaborations, JVs and partnerships
14 Global Companion Diagnostics Market Company Profile (Key Players)
14.1 Market Share, Company Revenue, Products, M&A, Developments
14.2 F. Hoffmann-La Roche AG
14.3 Agilent Technologies, Inc.
14.4 QIAGEN N.V.
14.5 Danaher Corporation
14.6 Abbott Laboratories, Inc.
14.7 Biomérieux SA
14.8 Myriad Genetics, Inc.
14.9 Sysmex Corporation
14.10 Almac Group
14.11 Illumina Inc.
14.12 Company 11 & more
15 Global Companion Diagnostics Market – Appendix
15.1 Sources
15.2 Abbreviations